Helomics® to Present at Canaccord Genuity Medical Technology & Diagnostics Forum

PITTSBURGH–(BUSINESS WIRE)–Helomics Corporation, a privately held comprehensive personalized
healthcare company that develops innovative next generation diagnostics
for the oncology field, announced today that it will present at the
Canaccord Genuity Medical Technology & Diagnostics Forum to be held
November 19, 2015, at The Westin New York Grand Central in New York.

Dane Saglio, Vice President and Chief Financial Officer of Helomics,
will provide an overview of the Company’s business during his live
presentation and will be available to participate in one-on-one meetings
with investors who are registered to attend the conference.

           

Event:

Canaccord Genuity Medical Technology and Diagnostics Forum

Date:

Thursday, November 19, 2015

Time:

9:00AM

Location:

The Westin New York Grand Central
 

About Helomics® Corporation

Helomics® is a comprehensive personalized healthcare company,
bringing the next generation of diagnostics to the oncology field.
Helomics is dedicated to improving patient outcomes by providing a
comprehensive personalized tumor profile utilizing a proprietary set of
laboratory platforms that leverage both live and fixed cellular analysis
to allow physicians to personally characterize malignant tumors.
Helomics’ novel molecular and cellular markers and bioinformatics
services are designed to support treatment decisions by providing vital
information based on the specific biological processes of each
individual’s cancer.

Helomics is headquartered in Pittsburgh, Pennsylvania where the company
maintains two CLIA-certified laboratories. For more information please
visit: www.helomics.com.

Contacts

Helomics Contacts:
Tiberend
Strategic Advisors, Inc.

Joshua Drumm, Ph.D. – Investors
212-375-2664
jdrumm@tiberend.com
or
Claire
Sojda – Media
212-375-2686
csojda@tiberend.com